Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality

Summary Background A multi‐society consensus group proposed a new nomenclature for steatotic liver disease (SLD) including metabolic‐dysfunction associated steatotic liver disease (MASLD), MASLD and increased alcohol intake (MetALD) and alcohol‐associated liver disease (ALD). However, the risk of li...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Alimentary pharmacology & therapeutics 2024-07, Vol.60 (1), p.61-69
Hauptverfasser: Tamaki, Nobuharu, Kimura, Takefumi, Wakabayashi, Shun‐Ichi, Umemura, Takeji, Kurosaki, Masayuki, Loomba, Rohit, Izumi, Namiki
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 69
container_issue 1
container_start_page 61
container_title Alimentary pharmacology & therapeutics
container_volume 60
creator Tamaki, Nobuharu
Kimura, Takefumi
Wakabayashi, Shun‐Ichi
Umemura, Takeji
Kurosaki, Masayuki
Loomba, Rohit
Izumi, Namiki
description Summary Background A multi‐society consensus group proposed a new nomenclature for steatotic liver disease (SLD) including metabolic‐dysfunction associated steatotic liver disease (MASLD), MASLD and increased alcohol intake (MetALD) and alcohol‐associated liver disease (ALD). However, the risk of liver‐related events, major adverse cardiovascular events (MACE) and all‐cause mortality among various sub‐groups is unknown. Aims To evaluate the risk of liver‐related events, MACE and death among patients with SLD. Methods We conducted a nationwide, population‐based study and enrolled 761,400 patients diagnosed with MASLD, MetALD or ALD. The primary endpoint was the occurrence of liver‐related events, MACE and death in patients with MASLD, MetALD and ALD. Results The cumulative incidence of liver‐related events and death were highest in ALD, followed by MetALD and MASLD (p 
doi_str_mv 10.1111/apt.18015
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3047948769</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3066183072</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3535-d2a2996ec539f66857045cc84fab26d7d97ad3a2c238a895ba026398d9da51cc3</originalsourceid><addsrcrecordid>eNp1kc-KFDEQh4Mo7rh68AUk4EXB3k0nk3RyXJb1DwzoYT03NUm1ZEl3xiQ9y9x8hPUVfRKz26MHwVwKUl99FPUj5GXLztr6zmFXzlrNWvmIrFqhZMOZUI_JinFlGq5bcUKe5XzDGFMd40_JidBKrXWnVuTnJk7ffv24K5hGaoOfvIVA41xsHDFTP9FcEEos3tLg95io8xkhI4XJ1bb1DieLNA5Lu6oSBijoKO5xKvkdtZCcj3vIdg6Qjt8P4xBC5S3MVTfGVCD4cnhOngwQMr441lPy9f3V9eXHZvP5w6fLi01jhRSycRy4MQqtFGZQSsuOraW1ej3AlivXOdOBE8AtFxq0kVuo1xBGO-NAttaKU_Jm8e5S_D5jLv3os8UQYMI4516wdWfuj2Qq-vof9CbOaarbVUqpVgvW8Uq9XSibYs4Jh36X_Ajp0Lesv8-przn1DzlV9tXROG9HdH_JP8FU4HwBbn3Aw_9N_cWX60X5G6lmobk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3066183072</pqid></control><display><type>article</type><title>Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library All Journals</source><creator>Tamaki, Nobuharu ; Kimura, Takefumi ; Wakabayashi, Shun‐Ichi ; Umemura, Takeji ; Kurosaki, Masayuki ; Loomba, Rohit ; Izumi, Namiki</creator><creatorcontrib>Tamaki, Nobuharu ; Kimura, Takefumi ; Wakabayashi, Shun‐Ichi ; Umemura, Takeji ; Kurosaki, Masayuki ; Loomba, Rohit ; Izumi, Namiki</creatorcontrib><description>Summary Background A multi‐society consensus group proposed a new nomenclature for steatotic liver disease (SLD) including metabolic‐dysfunction associated steatotic liver disease (MASLD), MASLD and increased alcohol intake (MetALD) and alcohol‐associated liver disease (ALD). However, the risk of liver‐related events, major adverse cardiovascular events (MACE) and all‐cause mortality among various sub‐groups is unknown. Aims To evaluate the risk of liver‐related events, MACE and death among patients with SLD. Methods We conducted a nationwide, population‐based study and enrolled 761,400 patients diagnosed with MASLD, MetALD or ALD. The primary endpoint was the occurrence of liver‐related events, MACE and death in patients with MASLD, MetALD and ALD. Results The cumulative incidence of liver‐related events and death were highest in ALD, followed by MetALD and MASLD (p &lt; 0.001 for both liver‐related events and death), while the incidence of MACE was highest in MASLD, followed by MetALD and ALD (p &lt; 0.001). Using MASLD as the reference and adjusting for age, sex, smoking, diabetes mellitus, dyslipidaemia and hypertension, the adjusted hazard ratios (95% confidence intervals) for liver‐related events, MACE and death in MetALD were 1.42 (1.1–1.8), 0.68 (0.63–0.73) and 1.13 (0.98–1.3), respectively. In ALD, they were 3.42 (2.6–4.6), 0.58 (0.49–0.67) and 1.60 (1.3–2.0), respectively, for liver‐related events, MACE and death. Conclusions The new consensus nomenclature can be used to stratify the risk of complications and prognosis. The nomenclature is beneficial for risk stratification and identifying new mechanisms for disease‐specific therapeutic implications. The cumulative incidence of liver‐related events and death were highest in ALD, followed by MetALD and MASLD, while the incidence of MACE was highest in MASLD, followed by MetALD and ALD. Therefore, the new consensus nomenclature can be used to stratify the risk of complications and prognosis.</description><identifier>ISSN: 0269-2813</identifier><identifier>ISSN: 1365-2036</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1111/apt.18015</identifier><identifier>PMID: 38664876</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Death ; Diabetes mellitus ; Dyslipidemia ; Liver diseases ; Mortality ; Nomenclature ; Population studies</subject><ispartof>Alimentary pharmacology &amp; therapeutics, 2024-07, Vol.60 (1), p.61-69</ispartof><rights>2024 John Wiley &amp; Sons Ltd.</rights><rights>Copyright © 2024 John Wiley &amp; Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3535-d2a2996ec539f66857045cc84fab26d7d97ad3a2c238a895ba026398d9da51cc3</citedby><cites>FETCH-LOGICAL-c3535-d2a2996ec539f66857045cc84fab26d7d97ad3a2c238a895ba026398d9da51cc3</cites><orcidid>0000-0003-4634-6616 ; 0000-0002-1481-1029</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fapt.18015$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fapt.18015$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38664876$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tamaki, Nobuharu</creatorcontrib><creatorcontrib>Kimura, Takefumi</creatorcontrib><creatorcontrib>Wakabayashi, Shun‐Ichi</creatorcontrib><creatorcontrib>Umemura, Takeji</creatorcontrib><creatorcontrib>Kurosaki, Masayuki</creatorcontrib><creatorcontrib>Loomba, Rohit</creatorcontrib><creatorcontrib>Izumi, Namiki</creatorcontrib><title>Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality</title><title>Alimentary pharmacology &amp; therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>Summary Background A multi‐society consensus group proposed a new nomenclature for steatotic liver disease (SLD) including metabolic‐dysfunction associated steatotic liver disease (MASLD), MASLD and increased alcohol intake (MetALD) and alcohol‐associated liver disease (ALD). However, the risk of liver‐related events, major adverse cardiovascular events (MACE) and all‐cause mortality among various sub‐groups is unknown. Aims To evaluate the risk of liver‐related events, MACE and death among patients with SLD. Methods We conducted a nationwide, population‐based study and enrolled 761,400 patients diagnosed with MASLD, MetALD or ALD. The primary endpoint was the occurrence of liver‐related events, MACE and death in patients with MASLD, MetALD and ALD. Results The cumulative incidence of liver‐related events and death were highest in ALD, followed by MetALD and MASLD (p &lt; 0.001 for both liver‐related events and death), while the incidence of MACE was highest in MASLD, followed by MetALD and ALD (p &lt; 0.001). Using MASLD as the reference and adjusting for age, sex, smoking, diabetes mellitus, dyslipidaemia and hypertension, the adjusted hazard ratios (95% confidence intervals) for liver‐related events, MACE and death in MetALD were 1.42 (1.1–1.8), 0.68 (0.63–0.73) and 1.13 (0.98–1.3), respectively. In ALD, they were 3.42 (2.6–4.6), 0.58 (0.49–0.67) and 1.60 (1.3–2.0), respectively, for liver‐related events, MACE and death. Conclusions The new consensus nomenclature can be used to stratify the risk of complications and prognosis. The nomenclature is beneficial for risk stratification and identifying new mechanisms for disease‐specific therapeutic implications. The cumulative incidence of liver‐related events and death were highest in ALD, followed by MetALD and MASLD, while the incidence of MACE was highest in MASLD, followed by MetALD and ALD. Therefore, the new consensus nomenclature can be used to stratify the risk of complications and prognosis.</description><subject>Death</subject><subject>Diabetes mellitus</subject><subject>Dyslipidemia</subject><subject>Liver diseases</subject><subject>Mortality</subject><subject>Nomenclature</subject><subject>Population studies</subject><issn>0269-2813</issn><issn>1365-2036</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp1kc-KFDEQh4Mo7rh68AUk4EXB3k0nk3RyXJb1DwzoYT03NUm1ZEl3xiQ9y9x8hPUVfRKz26MHwVwKUl99FPUj5GXLztr6zmFXzlrNWvmIrFqhZMOZUI_JinFlGq5bcUKe5XzDGFMd40_JidBKrXWnVuTnJk7ffv24K5hGaoOfvIVA41xsHDFTP9FcEEos3tLg95io8xkhI4XJ1bb1DieLNA5Lu6oSBijoKO5xKvkdtZCcj3vIdg6Qjt8P4xBC5S3MVTfGVCD4cnhOngwQMr441lPy9f3V9eXHZvP5w6fLi01jhRSycRy4MQqtFGZQSsuOraW1ej3AlivXOdOBE8AtFxq0kVuo1xBGO-NAttaKU_Jm8e5S_D5jLv3os8UQYMI4516wdWfuj2Qq-vof9CbOaarbVUqpVgvW8Uq9XSibYs4Jh36X_Ajp0Lesv8-przn1DzlV9tXROG9HdH_JP8FU4HwBbn3Aw_9N_cWX60X5G6lmobk</recordid><startdate>202407</startdate><enddate>202407</enddate><creator>Tamaki, Nobuharu</creator><creator>Kimura, Takefumi</creator><creator>Wakabayashi, Shun‐Ichi</creator><creator>Umemura, Takeji</creator><creator>Kurosaki, Masayuki</creator><creator>Loomba, Rohit</creator><creator>Izumi, Namiki</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>H94</scope><scope>M7N</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4634-6616</orcidid><orcidid>https://orcid.org/0000-0002-1481-1029</orcidid></search><sort><creationdate>202407</creationdate><title>Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality</title><author>Tamaki, Nobuharu ; Kimura, Takefumi ; Wakabayashi, Shun‐Ichi ; Umemura, Takeji ; Kurosaki, Masayuki ; Loomba, Rohit ; Izumi, Namiki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3535-d2a2996ec539f66857045cc84fab26d7d97ad3a2c238a895ba026398d9da51cc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Death</topic><topic>Diabetes mellitus</topic><topic>Dyslipidemia</topic><topic>Liver diseases</topic><topic>Mortality</topic><topic>Nomenclature</topic><topic>Population studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tamaki, Nobuharu</creatorcontrib><creatorcontrib>Kimura, Takefumi</creatorcontrib><creatorcontrib>Wakabayashi, Shun‐Ichi</creatorcontrib><creatorcontrib>Umemura, Takeji</creatorcontrib><creatorcontrib>Kurosaki, Masayuki</creatorcontrib><creatorcontrib>Loomba, Rohit</creatorcontrib><creatorcontrib>Izumi, Namiki</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>MEDLINE - Academic</collection><jtitle>Alimentary pharmacology &amp; therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tamaki, Nobuharu</au><au>Kimura, Takefumi</au><au>Wakabayashi, Shun‐Ichi</au><au>Umemura, Takeji</au><au>Kurosaki, Masayuki</au><au>Loomba, Rohit</au><au>Izumi, Namiki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality</atitle><jtitle>Alimentary pharmacology &amp; therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>2024-07</date><risdate>2024</risdate><volume>60</volume><issue>1</issue><spage>61</spage><epage>69</epage><pages>61-69</pages><issn>0269-2813</issn><issn>1365-2036</issn><eissn>1365-2036</eissn><abstract>Summary Background A multi‐society consensus group proposed a new nomenclature for steatotic liver disease (SLD) including metabolic‐dysfunction associated steatotic liver disease (MASLD), MASLD and increased alcohol intake (MetALD) and alcohol‐associated liver disease (ALD). However, the risk of liver‐related events, major adverse cardiovascular events (MACE) and all‐cause mortality among various sub‐groups is unknown. Aims To evaluate the risk of liver‐related events, MACE and death among patients with SLD. Methods We conducted a nationwide, population‐based study and enrolled 761,400 patients diagnosed with MASLD, MetALD or ALD. The primary endpoint was the occurrence of liver‐related events, MACE and death in patients with MASLD, MetALD and ALD. Results The cumulative incidence of liver‐related events and death were highest in ALD, followed by MetALD and MASLD (p &lt; 0.001 for both liver‐related events and death), while the incidence of MACE was highest in MASLD, followed by MetALD and ALD (p &lt; 0.001). Using MASLD as the reference and adjusting for age, sex, smoking, diabetes mellitus, dyslipidaemia and hypertension, the adjusted hazard ratios (95% confidence intervals) for liver‐related events, MACE and death in MetALD were 1.42 (1.1–1.8), 0.68 (0.63–0.73) and 1.13 (0.98–1.3), respectively. In ALD, they were 3.42 (2.6–4.6), 0.58 (0.49–0.67) and 1.60 (1.3–2.0), respectively, for liver‐related events, MACE and death. Conclusions The new consensus nomenclature can be used to stratify the risk of complications and prognosis. The nomenclature is beneficial for risk stratification and identifying new mechanisms for disease‐specific therapeutic implications. The cumulative incidence of liver‐related events and death were highest in ALD, followed by MetALD and MASLD, while the incidence of MACE was highest in MASLD, followed by MetALD and ALD. Therefore, the new consensus nomenclature can be used to stratify the risk of complications and prognosis.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>38664876</pmid><doi>10.1111/apt.18015</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-4634-6616</orcidid><orcidid>https://orcid.org/0000-0002-1481-1029</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0269-2813
ispartof Alimentary pharmacology & therapeutics, 2024-07, Vol.60 (1), p.61-69
issn 0269-2813
1365-2036
1365-2036
language eng
recordid cdi_proquest_miscellaneous_3047948769
source EZB-FREE-00999 freely available EZB journals; Wiley Online Library All Journals
subjects Death
Diabetes mellitus
Dyslipidemia
Liver diseases
Mortality
Nomenclature
Population studies
title Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T20%3A41%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long%E2%80%90term%20clinical%20outcomes%20in%20steatotic%20liver%20disease%20and%20incidence%20of%20liver%E2%80%90related%20events,%20cardiovascular%20events%20and%20all%E2%80%90cause%20mortality&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=Tamaki,%20Nobuharu&rft.date=2024-07&rft.volume=60&rft.issue=1&rft.spage=61&rft.epage=69&rft.pages=61-69&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1111/apt.18015&rft_dat=%3Cproquest_cross%3E3066183072%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3066183072&rft_id=info:pmid/38664876&rfr_iscdi=true